Clinical Trial Update: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer [Phase 1]

View source ↗

Summary

This Phase 1 dose-escalation trial of taselisib (GDC-0032) in locally advanced or metastatic solid tumors or Non-Hodgkin lymphoma, including combination with en…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer
• Non-hodgkin Lymphoma

Drugs mentioned

• GDC-0032 (taselisib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Solid Cancers, Non-Hodgkin's Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2024-07-31